Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

MindScape Retreat Emerges as Global Leader in Ibogaine Therapy for Neurological and Mental Health Disorders


News provided by

MindScape Retreat

Apr 23, 2025, 20:20 ET

Share this article

Share toX

Share this article

Share toX

Ibogaine Treatment Center
Ibogaine Treatment Center

As scientific interest in psychedelic-assisted therapies continues to surge, MindScape Retreat, a licensed Ibogaine treatment facility located on the peaceful island of Cozumel, Mexico, is establishing itself as the global leader in Ibogaine-based neurotherapy. With a growing body of clinical case studies and a scientifically integrated treatment protocol, MindScape is advancing care for complex disorders including Parkinson's disease, PTSD, treatment-resistant depression, anxiety, SSRI tapering, addiction, OCD, and multiple sclerosis (MS).

COZUMEL, Mexico, April 23, 2025 /PRNewswire-PRWeb/ -- As scientific interest in psychedelic-assisted therapies continues to surge, MindScape Retreat, a licensed Ibogaine treatment center located on the peaceful island of Cozumel, Mexico, is establishing itself as the global leader in Ibogaine-based neurotherapy. With a growing body of clinical case studies and a scientifically integrated treatment protocol, MindScape is advancing care for complex disorders including Parkinson's disease, PTSD, treatment-resistant depression, anxiety, SSRI tapering, addiction, OCD, and multiple sclerosis (MS).

Clinical Research and Case Study Development

In collaboration with international medical researchers and academic consultants, MindScape Retreat is conducting a comprehensive, data-driven case study series to evaluate the safety and efficacy of Ibogaine for both neurological and psychiatric indications. Each patient undergoing treatment for conditions like Parkinson's or PTSD is monitored through:

  • Unified Parkinson's Disease Rating Scale (UPDRS)
  • Montreal Cognitive Assessment (MoCA)
  • Hamilton Depression Rating Scale (HAM-D)
  • State-Trait Anxiety Inventory (STAI)
  • Timed Up & Go (TUG) Test
  • Pre- and post-treatment blood biomarkers for neuroinflammation and oxidative stress

These measures are part of a prospective cohort design that tracks changes in motor function, mood, cognitive performance, and quality of life. The retreat plans to submit its first peer-reviewed publication by mid-2025, presenting outcomes from over 30 patients across multiple diagnostic categories. Early data indicates notable improvements in motor symptoms for Parkinson's patients, significant reduction in PTSD symptom clusters, and successful discontinuation of SSRIs in long-term users.

How Ibogaine Works: Neuroregeneration at the Molecular Level

Unlike conventional pharmacotherapy, which often targets symptoms through receptor blocking or neurotransmitter reuptake inhibition, Ibogaine acts systemically, promoting long-term neural repair and functional restoration. Scientifically, its mechanisms of action include:

  • Stimulation of Glial Cell-Derived Neurotrophic Factor (GDNF): Essential for dopaminergic neuron survival, GDNF supports repair in Parkinson's disease and dopamine depletion from addiction or SSRI withdrawal.
  • Increase in Brain-Derived Neurotrophic Factor (BDNF): Promotes synaptic plasticity and neurogenesis, beneficial for cognitive restoration in trauma-related disorders and neurodegeneration.
  • Dopaminergic and Serotonergic Modulation: Ibogaine resets dysregulated dopamine and serotonin pathways, which are central to mood, motivation, addiction, and obsessive-compulsive patterns.
  • NMDA Receptor Antagonism: Reduces excitotoxicity and neuroinflammation, two key contributors to progressive neurological diseases.

The therapy is further enhanced with NAD⁺ infusions, which improve mitochondrial energy metabolism and cellular repair, and 5-MeO-DMT therapy, offering an emotional integration experience post-Ibogaine.

Why Cozumel? Safety and Serenity for Healing

While Ibogaine treatment has gained attention in cities like Tijuana and Cancun, MindScape Retreat's location in Cozumel provides unmatched safety, privacy, and tranquility. Unlike border cities known for higher crime rates or medical tourism saturation, Cozumel is an island sanctuary, offering:

  • A secure and peaceful environment, away from the overstimulation of urban areas.
  • Consistent access to emergency medical support and direct collaboration with nearby hospitals.
  • Fully licensed, government-compliant protocols, ensuring legal and ethical treatment standards.

This geographical advantage allows for deeper patient focus, tighter medical supervision, and reduced risk of environmental stress, which is critical during intensive psychedelic therapy.

What's Next for MindScape Retreat

With its forthcoming case study publication and partnerships with international researchers, MindScape Retreat aims to be at the forefront of psychedelic science applied to neurodegeneration and complex mental health disorders. As regulatory conversations around Ibogaine expand in the U.S., MindScape continues to offer a gold-standard, evidence-based model for how this powerful medicine can be responsibly administered.

For media inquiries, research collaborations, or treatment inquiries, contact:

[email protected]

+1 786-761-7729

https://www.mindscaperetreat.com/ibogaine-treatment-clinic

About MindScape Retreat:

MindScape Retreat is a fully licensed and medically supervised Ibogaine treatment center in Cozumel, Mexico. The center specializes in treating neurological and mental health conditions through Ibogaine, 5-MeO-DMT, and NAD⁺ protocols, supported by rigorous scientific methodology and holistic wellness practices.

Media Contact

Dr Calderon, MindScape Retreat, 1 786-761-7729, [email protected], https://www.mindscaperetreat.com/ibogaine-treatment-clinic

SOURCE MindScape Retreat

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.